BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 15971099)

  • 21. [Transsphenoidal microsurgical results of non-invasive prolactinomas].
    Xu ZQ; Su CB; Ren ZY; Wang RZ; Yang Y; Ma WB; Li YN; Xing B; Lian W; Yang Z
    Zhonghua Wai Ke Za Zhi; 2008 Feb; 46(4):293-5. PubMed ID: 18683769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microprolactinomas in males treated by transsphenoidal surgery.
    Wolfsberger S; Czech T; Vierhapper H; Benavente R; Knosp E
    Acta Neurochir (Wien); 2003 Nov; 145(11):935-40; discussion 940-1. PubMed ID: 14628197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gamma knife radiosurgery for medically and surgically refractory prolactinomas.
    Pouratian N; Sheehan J; Jagannathan J; Laws ER; Steiner L; Vance ML
    Neurosurgery; 2006 Aug; 59(2):255-66; discussion 255-66. PubMed ID: 16883166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
    Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of surgery for the treatment of prolactinomas.
    van't Verlaat JW
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
    Passos VQ; Souza JJ; Musolino NR; Bronstein MD
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
    Kars M; Pereira AM; Smit JW; Romijn JA
    Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment strategy of pituitary invasive prolactinomas].
    Wu ZB; Yu CJ
    Zhonghua Wai Ke Za Zhi; 2009 Jan; 47(2):123-7. PubMed ID: 19563008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Results of treatment for male prolactinomas].
    Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
    No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
    Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
    Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-surgical management of cystic prolactinomas.
    Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
    J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.